# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001564590-22-036619
Filing Date
2022-11-03
Accepted
2022-11-03 16:20:51
Documents
3

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | abio-defa14a_20221215.htm | DEFA14A | 19641
2 | GRAPHIC | g2hn4cgz0sih000001.jpg | GRAPHIC | 583733
3 | GRAPHIC | g2hn4cgz0sih000002.jpg | GRAPHIC | 344260
| Complete submission text file | 0001564590-22-036619.txt |  | 1298761

Mailing Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021
Business Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021 7209402200
ARCA biopharma, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-22873 | Film No.: 221358364
SIC: 2835 In Vitro & In Vivo Diagnostic Substances